Efficient delivery of shRNAs to cancer cells is crucial for their therapeutic application. Common delivery methods include viral vectors (such as lentiviruses, adenoviruses, and retroviruses), lipid nanoparticles, and conjugation with targeting moieties like antibodies. Each method has its own advantages and limitations. For example, viral vectors can achieve high transduction efficiency but may pose safety concerns, whereas lipid nanoparticles are generally safer but may have lower delivery efficiency.
